Here are three things to know.
1. Trogarzo is an antiretroviral medication for adult patients with HIV who do not respond to other HIV therapies on the market.
2. Clinicians administer the intravenous drug to a patient once every two weeks.
3. The drug should be used in combination with other antiretroviral medications.
“While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have multidrug-resistant HIV, limiting their treatment options and putting them at a high risk of HIV-related complications and progression to death,” said Jeff Murray, MD, deputy director of the division of antiviral products in the FDA’s Center for Drug Evaluation and Research. “Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options.”
More articles on supply chain:
Teva shutters offices in New York City, Washington D.C., as part of cost cutting plan
AbbVie, Biogen pull multiple sclerosis drug from the market citing safety concerns: 4 things to know
Amazon ‘poaches’ 20 jobs from CVS, Express Scripts, UnitedHealth: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.